Nuvation Bio Inc.
Clinical trials sponsored by Nuvation Bio Inc., explained in plain language.
-
Promising pill aims to stop lung Cancer's return in High-Risk patients
Disease control Recruiting nowThis study tests whether the drug taletrectinib can prevent non-small cell lung cancer from returning in people whose tumors have been fully removed by surgery. About 180 adults with a specific genetic marker (ROS1-fusion) and stage IB to IIIA cancer will receive either taletrect…
Phase: PHASE3 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated May 17, 2026 00:52 UTC
-
New hope for brain tumor patients: targeted drug enters final testing phase
Disease control Recruiting nowThis study tests a drug called safusidenib in people with a slow-growing brain tumor (glioma) that has a specific IDH1 gene mutation. The trial has three parts: one for recurrent tumors, one to see if the drug can prevent tumor growth after standard treatment, and one for a speci…
Phase: PHASE3 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New hope for rare lung cancer: taletrectinib takes on crizotinib in phase 3 showdown
Disease control Recruiting nowThis study compares a new drug, taletrectinib, to the standard drug crizotinib in people with a specific type of advanced lung cancer (ROS1-positive non-small cell lung cancer) who have not had prior targeted therapy. About 194 participants will be randomly assigned to take eithe…
Phase: PHASE3 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated May 12, 2026 13:41 UTC